Velafbalanceret central serotonin - og dopaminantagonisme kan nedsætte risikoen for ekstrapyramidale symptomer og øge den terapeutiske effekt over for skizofreniens negative og affektive symptomer.
Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.